Skip to main content
. 2017 Mar 21;8(23):37511–37524. doi: 10.18632/oncotarget.16400

Figure 4. Differentiation changes of GSC-initiated heterotopic gliomas after treatment of QUE, TMZ or combined QUE and TMZ.

Figure 4

(A) Representative immunohistochemistry of PCNA, Nestin, Olig2, MBP, and GFAP in GSC-initiated heterotopic xenograft gliomas after 21-day treatment of QUE, TMZ or combined QUE+TMZ vs controls (VEH). (B) Quantitative analysis, from photomicrographs, for the immunohistochemistry results of cellular markers in GSC-initiated gliomas after treatment of QUE, TMZ or combined QUE+TMZ for 21 days. *P <0.05. **P<0.01 vs VEH. Scale bar: 20μm.